Psychotropic drugs and COVID-19: therapeutic management

Authors

  • Victor Hugo Schaly Cordova Faculdade de Farmácia Universidade Federal do Rio Grande do Sul UFRGS, Porto Alegre-RS. Av. Ipiranga, 2752 - Azenha, Porto Alegre - RS, 90610-000 http://orcid.org/0000-0001-6147-1250
  • Paulo Silva Belmonte-de-Abreu Faculdade de Medicina UFRGS Universidade Federal do Rio Grande do Sul, Porto Alegre-RS R. Ramiro Barcelos, 2400 - Santa Cecília CEP: 90035-002 http://orcid.org/0000-0002-2853-2004

DOI:

https://doi.org/10.14450/2318-9312.v35.e2.a2023.pp148-190

Keywords:

Schizophrenia, bipolar disorder, depression, psychopharmaceutical, COVID-19, SARS-CoV-2.

Abstract

In March 2020, the World Health Organization (WHO) declared a pandemic due to the SARS-CoV-2/COVID-19 virus. At the beginning of 2021, it was recorded 83,715,617 confirmed cases and 1,835,901 deaths by COVID-19. Thus, a worldwide effort was made to develop effective protocols to treat this disease. One of the difficulties was the heterogeneity with which COVID-19 affects different patients due to comorbidities. The lack of specific drugs to treat COVID-19 is worrying. This situation is even worst when we consider possible interactions between these drugs and those previously used, mainly those of chronic use. In this context are patients with psychiatric disorders, such as Major Depressive Disorder (MDD), Bipolar Affective Disorder (BAD), and Schizophrenia. This work aimed to identify the most cited drugs in COVID-19 treatment and evaluate their interactions with drugs described in treatment protocols for mood and psychotic disorders. A narrative review of the most cited drugs for COVID-19 in different stages of the disease on safety and efficacy in patients on treatment for depression, bipolar disorder, and schizophrenia was made. Non-clinical trials, trials without results, articles that present later retraction, articles written in unfamiliar foreign languages to the authors, and vaccine-related articles and immune therapy were excluded because they are out of the scope of this study. After exclusions, 117 studies were considered. The most cited drugs were Hydroxychloroquine/Chloroquine (26 articles), followed by tocilizumab (10 articles), ivermectin and remdesivir (8 articles each), and favipiravir (7 articles). Hydroxychloroquine/chloroquine showed several conflicting results and was the drug most associated with drug interactions in all studied drugs.

Author Biographies

Victor Hugo Schaly Cordova, Faculdade de Farmácia Universidade Federal do Rio Grande do Sul UFRGS, Porto Alegre-RS. Av. Ipiranga, 2752 - Azenha, Porto Alegre - RS, 90610-000

Farmacêutico e mestrando em Psiquiatria e Ciências do Comportamento pela Universidade Federal do Rio Grande do Sul, Biólogo pela Universidade do Extremo Sul Catarinense e Técnico em Patologia Clínica pelo Centro Educacional Abílio Paulo. Bolsista do programa PROEX da CAPES

Paulo Silva Belmonte-de-Abreu, Faculdade de Medicina UFRGS Universidade Federal do Rio Grande do Sul, Porto Alegre-RS R. Ramiro Barcelos, 2400 - Santa Cecília CEP: 90035-002

Professor Associado do Departamento de Psiquiatria da Faculdade de Medicina da Universidade Federal do Rio Grande do SUl

Downloads

Published

2023-07-03

How to Cite

Cordova, V. H. S., & Belmonte-de-Abreu, P. S. (2023). Psychotropic drugs and COVID-19: therapeutic management. Infarma - Pharmaceutical Sciences, 35(2), 148–190. https://doi.org/10.14450/2318-9312.v35.e2.a2023.pp148-190

Issue

Vol. 35 No. 2 (2023)

Section

Review Article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).